RELAPSED/REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA
Clinical trials for RELAPSED/REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA explained in plain language.
Never miss a new study
Get alerted when new RELAPSED/REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA trials appear
Sign up with your email to follow new studies for RELAPSED/REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Can immune cells plus a checkpoint drug outsmart lymphoma?
Disease control OngoingThis early-stage trial is testing whether a combination of tumor-specific immune cells (TAA-T) and the drug nivolumab can safely help people with lymphoma that has returned or not responded to treatment. Participants receive two infusions of TAA-T cells along with nivolumab, whic…
Matched conditions: RELAPSED/REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA
Phase: PHASE1 • Sponsor: Catherine Bollard • Aim: Disease control
Last updated Aug 16, 2026 00:00 UTC
-
Can a cancer drug reboot the immune system after a stem cell transplant?
Disease control OngoingThis phase 2 trial tests whether adding isatuximab to standard stem cell transplant procedures can help the immune system better fight multiple myeloma and certain lymphomas. Participants are randomly assigned to receive either standard transplant care alone or isatuximab plus st…
Matched conditions: RELAPSED/REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA
Phase: PHASE2 • Sponsor: Divaya Bhutani • Aim: Disease control
Last updated Jul 25, 2026 00:00 UTC
-
New combo therapy hopes to tackle tough lymphoma
Disease control OngoingThis trial tests two new drug combinations (glofitamab plus atezolizumab or polatuzumab vedotin) in adults with B-cell non-Hodgkin lymphoma that has returned or not responded to prior treatment. The study aims to find the safest dose and see if these combos shrink tumors. About 2…
Matched conditions: RELAPSED/REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA
Phase: PHASE1, PHASE2 • Sponsor: Hoffmann-La Roche • Aim: Disease control
Last updated Jul 08, 2026 00:00 UTC
-
New pill combo aims to tackle tough lymphoma when other treatments fail
Disease control OngoingThis study tests whether adding the oral drug selinexor to standard chemotherapy (R-GDP) can help people with relapsed or refractory diffuse large B-cell lymphoma who cannot receive a stem cell transplant or CAR-T therapy. About 500 participants will receive either selinexor at o…
Matched conditions: RELAPSED/REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA
Phase: PHASE2, PHASE3 • Sponsor: Karyopharm Therapeutics Inc • Aim: Disease control
Last updated Jul 04, 2026 00:00 UTC
-
Promising new combo therapy targets hard-to-treat lymphoma
Disease control OngoingThis study tests a new treatment for people with a type of blood cancer called diffuse large B-cell lymphoma that has come back or not responded to prior therapy. The treatment combines two drugs (tafasitamab and lenalidomide) with standard chemotherapy, followed by a stem cell t…
Matched conditions: RELAPSED/REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA
Phase: PHASE2 • Sponsor: The First Affiliated Hospital of Soochow University • Aim: Disease control
Last updated Jun 27, 2026 13:00 UTC